Responsible Conduct in Nanomedicine Research: Environmental Concerns beyond the Common Rule

45 C.F.R. part 46, subpart A (2009).

45 C.F.R. part 46 (2009).

21 C.F.R. part 56 (2010).

45 C.F.R. § 46.111(a)(1) (2009).

45 C.F.R. § 46.111(a)(2) (2009).

45 C.F.R. § 46.116 (2009).

45 C.F.R. § 46.111(a)(7) (2009).

Kimmelman J. , Gene Transfer and the Ethics of First-in-Human Research: Lost in Translation (Cambridge: Cambridge University Press, 2009): at 1.

National Nanotechnology Initiative, available at <http://www.nano.gov/> (last visited November 19, 2012).

Oberdörster G. Oberdörster E. , and Oberdörster J. , “Nanotoxicity: An Emerging Discipline Evolving from Studies of Ultrafine Particles,” Environmental Health Perspectives 113, no. 7 (2005): 823–39, at 823.

Resnik D. B. and Tinkle S. S. , “Ethics in Nanomedicine,” Nanomedicine 2, no. 3 (2007): 345–350, at 345.

Resnik D. B. and Tinkle S. S. , “Ethical Issues in Clinical Trials Involving Nanomedicine,” Contemporary Clinical Trials 28, no. 4 (2007): 433–441, at 433.

See Oberdörster , supra note 10, at 823.

See National Nanotechnology Initiative, supra note 9.

Hoet P. Brüske-Hohlfield I. , and Salata O. , “Nanoparticles – Known and Unknown Health Risks,” Journal of Nanobiotechnology 2, no. 1(2004): 12–27, at 12.

Oberdörster G. , “Safety Assessment for Nanotechnology and Nanomedicine: Concepts of Nanotoxicology,” Journal of Internal Medicine 267, no. 1 (2010): 89–105, at 89.

See Oberdörster , supra note 10, at 823.

Allhoff F. Lin P. , and Moore D. , What Is Nanotechnology and Why Does It Matter? (New York: Wiley-Blackwell, 2010): at 71.

Resnik D. B. , “Is the Precautionary Principle Unscientific?” Studies in the History and Philosophy of Biology and the Biomedical Sciences 34, no. 2 (2003): 329–344, at 329.

Elliott K. , “Nanomaterials and the Precautionary Principle,” Environmental Health Perspectives 119, no. 6 (2011): A240.

Munthe C. , The Price of Precaution and the Ethics of Risk (Dordrecht: Springer, 2011): at 1.

See Oberdörster , supra note 16, at 89.

Yokel R. A. and Macphail R. C. , “Engineered Nanomaterials: Exposures, Hazards, and Risk Prevention,” Journal of Occupational Medicine and Toxicology 21, no. 6 (2011): 7.

See Yokel and Macpail , supra note 23, at 7.

Perry M. and Hu H. , “Workplace Health and Safety,” in Frumkin H. , ed., Environmental Health: From Global to Local, 2nd ed. (New York: John Wiley and Sons, 2010): 729–767, at 729.

Occupational Health and Safety Administration, “Nanotechnology: OSHA Standards,” available at <http://www.osha.gov/dsg/nanotechnology/nanotech_standards.html> (last visited November 19, 2012).

National Institute for Occupational Health and Safety, “Nanotechnology,” available at <http://www.cdc.gov/niosh/topics/nanotech/> (last visited November 19, 2012).

Environmental Protection Agency, “Control of Nanoscale Materials under the Toxic Substance Control Act,” available at <http://www.epa.gov/opptintr/nano/> (last visited November 19, 2012).

Cranor C. , Legally Poisoned: How the Law Puts Us at Risk from Toxicants (Cambridge, MA: Harvard University Press, 2011): at 208.

Davies J. C. , Managing the Effects of Nanotechnology (Washington, D.C.: Woodrow Wilson International Center, 2006): at 1.

National Institutes of Health, Office of Biotechnology Activities, “Institutional Biosafety Committees,” available at <http://oba.od.nih.gov/rdna_ibc/ibc.html> (last visited November 19, 2012).

Gunsalus C. K. Bruner E. M. Burbules N. C. Dash L. Finkin M. Goldberg J. P. Greenough W. T. Miller G. A. , and Pratt M. G. , “Mission Creep in the IRB World,” Science 312, no. 5779 (2006): 1441.

Resnik D. B. and Sharp R. , “Protecting Third Parties in Human Subjects Research,” IRB 28, no. 4 (2006): 1–7, at 1.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, The Belmont Report (Washington, D.C.: Department of Health, Education, and Welfare, 1979): at 1.

Beauchamp T. and Childress J. , Principles of Biomedical Ethics, 6th ed. (New York: Oxford University Press, 2008): at 165.

Weir T. , Introduction to Tort Law, 2nd ed. (Oxford: Oxford Higher Education, 2006): at 29.

Resnik D. B. , “Liability for Institutional Review Boards: From Regulation to Litigation,” Journal of Legal Medicine 25, no. 2 (2004): 131–184, at 131.

See Weir , supra note 36, at 29.

See Weir , supra note 36, at 29.

See Allhoff Lin , and Moore , supra note 18, at 71.

Sandler R. , Nanotechnology: The Social and Ethical Issues (Washington, D.C.: Woodrow Wilson International Center for Scholars, Project on Emerging Nanotechnologies, 2009): at 1.

See Allhoff Lin , and Moore , supra note 18, at 71.

Crichton M. , Prey (New York: Harper Collins, 2002): at 1.

Fleischman A. Eckenwiler L. Grady C. Hammerschmidt D. Levine C. , and Sugarman J. , “Dealing with the Long-Term Social Implications of Research,” American Journal of Bioethics 11, no. 5 (2011): 5–9, at 5.

See Fleischman , supra note 44, at 5.

Id.

World Medical Association, “WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects,” available at <http://www.wma.net/en/30publications/10policies/b3/> (last visited November 19, 2012).